Results 61 to 70 of about 10,449 (205)

Anticoagulant or Antithrombotic Therapy After Early Neurological Deterioration in Patients With Branch Atheromatous Disease Receiving Dual Antiplatelet Therapy

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objective We evaluated the effectiveness and safety of adding tirofiban or argatroban after early neurological deterioration (END) in patients with branch atheromatous disease (BAD) receiving dual antiplatelet therapy and compared the outcomes with those of patients who continued dual antiplatelet therapy alone. Methods This retrospective study focused
Xuemin Zhong, Juan Yang, Ronghua Xu, Jian Wang, Nikhat Kaura   +4 more
wiley   +1 more source

Platelet signalling networks: pathways perturbation demonstrates differential sensitivity of ADP secretion and fibinogen binding. [PDF]

, 2011
Platelet signalling responses to single agonists have been identified previously. However a model of the total platelet signalling network is still lacking.
De Chaumont, Ciaran, Lombardi, Federica, Moran, Niamh, Shields, Denis C   +3 more
core   +1 more source

Biomarkers in acute coronary syndromes and their role in diabetic patients [PDF]

, 2005
Diabetic patients with acute coronary syndromes are at high risk for cardiovascular complications but risk stratification in these patients remains challenging.
Christopher Heeschen, Heeschen C, James SK, Khaliq A, Luttun A, Mak KH   +5 more
core   +1 more source

Effects of Periprocedural Tirofiban vs. Oral Antiplatelet Drug Therapy on Posterior Circulation Infarction in Patients With Acute Intracranial Atherosclerosis-Related Vertebrobasilar Artery Occlusion

Frontiers in Neurology, 2020
Background and purpose: Tirofiban and oral antiplatelet drugs can be used to inhibit reocclusion and restore microvascular reperfusion during endovascular treatment (EVT).
Xuan Sun, Huijun Zhang, Xu Tong, Feng Gao, Gaoting Ma, Zhongrong Miao   +5 more
doaj   +1 more source

Association of LDL‐C With Angiographic Thrombus Burden in Patients With ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background High thrombus burden (HTB) during primary percutaneous coronary intervention (PCI) for ST‐segment elevation myocardial infarction (STEMI) is associated with adverse outcomes. Low‐density lipoprotein cholesterol (LDL‐C) is a key driver of atherosclerosis, but its direct role in acute thrombus formation remains unclear.
Tuo Han, Hytham H. Al-Samawi, Jing Xiao, Xiyu Gao, Gen Liu, Di Bai, Chunyan Zhang, Wei Jiang, Yan Zhang, Irfan Ahmad   +9 more
wiley   +1 more source

Administration of a Glycoprotein IIb/IIIa Receptor Blocker with a Thienopyridine Derivative Does Not Increase the Risk of Thrombocytopenia [PDF]

, 2005
Author Institution: Akron Cardiology Consulltants, OHAuthor Institution: Dept. of Educational Foundations & Leadership, University of Akron, OHAuthor Institution: Summa Health System, University of Akron, OHAuthor Institution: Dept.
Johnson, Jeremy, Josephson, Richard A., Newman, Isadore, Rohr, Susan M., Silver, Kevin H.   +4 more
core  

Safety and Efficacy of Tirofiban During Mechanical Thrombectomy for Stroke Patients with Preceding Intravenous Thrombolysis

Clinical Interventions in Aging, 2020
Xiaochuan Huo,1,2,* Ming Yang,1,2,* Ning Ma,1,2 Feng Gao,1,2 Dapeng Mo,1,2 Xiaoqing Li,1,2 Anxin Wang,2,3 Yongjun Wang,2,3 Zhongrong Miao1,2 1Department of Interventional Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing ...
Huo X, Yang M, Ma N, Gao F, Mo D, Li X, Wang A, Wang Y, Miao Z   +8 more
doaj  

Safety and efficacy of enoxaparin versus unfractionated heparins in conservatively managed patients with acute coronary syndrome: a systematic review

Journal of Pharmacy Practice and Research, Volume 55, Issue 6, Page 447-457, December 2025.
Abstract Aim Guidelines recommend initial anticoagulant management of acute coronary syndrome (ACS) with low molecular weight heparin (LMWH) such as enoxaparin or unfractionated heparin (UFH). Systematic reviews evaluate early trials in the context of multiple other medications or during percutaneous coronary intervention (PCI) only.
Krishna Doshi, Mark Jones, Laetitia Hattingh   +2 more
wiley   +1 more source

Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial

Stroke and Vascular Neurology
Background Perforating artery territorial infarction (PAI) caused by branch atheromatous disease (BAD) is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen.
Liping Liu, Yongjun Wang, Yilong Wang, Xingquan Zhao, Xiaoling Liao, Weiqi Chen, Yuesong Pan, Hui Qu, Shuo Feng, Yicong Wang   +9 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source